E-LIB Suche - Ergebnisse für: Van Der Velden, Vincent H.J

1

Association of Altered Plasma Lipidome with Disease Severit..:

Zhang, Zhengzheng ; Karu, Naama ; Kindt, Alida...
Biomolecules. 14 (2024) 3 - p. 296 , 2024

Link: https://doi.org/10.3390/..

2

Inotuzumab ozogamicin combined with chemotherapy in pediatr..:

Pennesi, Edoardo ; Brivio, Erica ; Ammerlaan, Anneke C. J....
Haematologica. , 2024

Link: https://doi.org/10.3324/..

3

The gray area of RQ-PCR-based measurable residual disease: ..:

Kotrova, Michaela ; Fronkova, Eva ; Svaton, Michael...
Leukemia. 38 (2024) 7 - p. 1617-1620 , 2024

Link: https://doi.org/10.1038/..

4

Benefits and risks of clofarabine in adult acute lymphoblas..:

Hermans, Sjoerd J. F. ; van Norden, Yvette ; Versluis, Jurjen...
Cancer Medicine. 13 (2024) 9 - p. , 2024

Link: https://doi.org/10.1002/..

5

The Evolving Landscape of Flowcytometric Minimal Residual D..:

Verbeek, Martijn W. C. ; van der Velden, Vincent H. J.
International Journal of Molecular Sciences. 25 (2024) 9 - p. 4881 , 2024

Link: https://doi.org/10.3390/..

6

Analysis of measurable residual disease by IG/TR gene rearr..:

van der Velden, Vincent H. J. ; Dombrink, Isabel ; Alten, Julia...
Leukemia. 38 (2024) 6 - p. 1315-1322 , 2024

Link: https://doi.org/10.1038/..

7

IKZF1 gene deletions drive resistance to cytarabine in B-ce..:

Vervoort, Britt M. T. ; Butler, Miriam ; Grünewald, Kari J.T....
Haematologica. , 2024

Link: https://doi.org/10.3324/..

8

ABL-class Genomic Breakpoint Q-PCR: A Patient-specific Appr..:

van Outersterp, Inge ; van der Velden, Vincent H.J. ; Hoogeveen, Patricia G....
HemaSphere. 7 (2023) 10 - p. e967 , 2023

Link: https://doi.org/10.1097/..

9

NGS better discriminates true MRD positivity for the risk s..:

Svaton, Michael ; Skotnicova, Aneta ; Reznickova, Leona...
Blood. 141 (2023) 5 - p. 529-533 , 2023

Link: https://doi.org/10.1182/..

10

Patient specific real-time PCR in precision medicine – Vali..:

Schilhabel, Anke ; Szczepanowski, Monika ; van Gastel-Mol, Ellen J....
Frontiers in Oncology. 12 (2023) - p. , 2023

Link: https://doi.org/10.3389/..

11

Minimal residual disease assessment in B‐cell precursor acu..:

Verbeek, Martijn W. C. ; Rodríguez, Beatriz Soriano ; Sedek, Lukasz...
Cytometry Part B: Clinical Cytometry. 106 (2023) 4 - p. 252-263 , 2023

Link: https://doi.org/10.1002/..

12

P872: EFFICACY OF DARATUMUMAB PLUS BORTEZOMIB, CYCLOPHOSPHA..:

Beksac, Meral ; Tuglular, Tulin ; Gay, Francesca...
HemaSphere. 7 (2023) S3 - p. e994593a , 2023

Link: https://doi.org/10.1097/..

13

Analytical assay validation for acute myeloid leukemia meas..:

Tettero, Jesse M. ; Dakappagari, Naveen ; Heidinga, Maaike E....
Cytometry Part B: Clinical Cytometry. 104 (2023) 6 - p. 426-439 , 2023

Link: https://doi.org/10.1002/..

14

Phenotypic profiling of CD34+ cells by advanced flow cytome..:

Bugarin, Cristina ; Antolini, Laura ; Buracchi, Chiara...
Haematologica. 109 (2023) 2 - p. 521-532 , 2023

Link: https://doi.org/10.3324/..

15

Severe COVID-19 Is Characterised by Perturbations in Plasma..:

Karu, Naama ; Kindt, Alida ; van Gammeren, Adriaan J....
Metabolites. 12 (2022) 7 - p. 618 , 2022

Link: https://doi.org/10.3390/..